Skip to main content
SpringerLink
Log in

Abdominal obesity, and not general obesity, is associated with a lower 123I MIBG heart-to-mediastinum ratio in heart failure patients with preserved ejection fraction

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Background

The relationship between general obesity or abdominal obesity (abdominal circumference of ≥85 cm in men and ≥ 90 cm in women) and the heart-to-mediastinum ratio (HMR), a measure of cardiac sympathetic innervation, on cardiac iodine-123-metaiodobenzylguanidine scintigraphy (MIBG) in patients with heart failure with preserved ejection fraction (HFpEF) has not been clarified.

Methods

A total of 239 HFpEF patients with both MIBG and abdominal circumference data were examined. We divided these patients into those with abdominal obesity and those without it. In the cardiac MIBG study, early phase image was acquired 15–20 min after injection, and late phase image was acquired 3 h after the early phase. A HMR obtained from a low-energy type collimator was converted to that obtained by a medium-energy type collimator.

Results

Early and late HMRs were significantly lower in those with abdominal obesity, although washout rates were not significantly different. The incidence of patients with early and late HMRs <2.2 was significantly higher in those with abdominal obesity. Multivariate linear regression analysis revealed that abdominal obesity was independently associated with early HMR (standardized β = −0.253, P = 0.003) and late HMR (standardized β = −0.222, P = 0.010). Multivariate logistic regression analysis revealed that abdominal obesity was independently associated with early (odds ratio [OR] [95% confidence interval {CI}] = 4.25 [2.13, 8.47], P < 0.001) and late HMR < 2.2 (OR [95% CI] = 2.06 [1.11, 3.83], P = 0.022). Elevated BMI was not significantly associated with low early and late HMR. The presence of abdominal obesity was significantly associated with low early and late HMR even in patients without elevated BMI values.

Conclusion

Abdominal obesity, but not general obesity, in HFpEF patients was independently associated with low HMR, suggesting that visceral fat may contribute to decreased cardiac sympathetic activity in patients with HFpEF.

Trial registration

UMIN000021831.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data availability

Not applicable.

References

  1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9.

    Article  CAS  Google Scholar 

  2. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126:65–75.

    Article  Google Scholar 

  3. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2012;33:1750–7.

    Article  Google Scholar 

  4. Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011;4:324–31.

    Article  Google Scholar 

  5. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J. 2009;73:1893–900.

    Article  Google Scholar 

  6. Nagai T, Yoshikawa T, Saito Y, Takeishi Y, Yamamoto K, Ogawa H, et al. Clinical characteristics, management, and outcomes of Japanese patients hospitalized for heart failure with preserved ejection fraction—a report from the Japanese Heart Failure Syndrome With Preserved Ejection Fraction (JASPER) Registry. Circ J. 2018;82:1534–45.

    Article  Google Scholar 

  7. Tanaka S, Horimai C, Katsukawa F. Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: a meta-analysis. Acta Diabetol. 2003;40:S302–4.

    Article  Google Scholar 

  8. National Health and Nutrition Survey 2018, Health Japan 21. Available from: https://www.nibiohn.go.jp/eiken/kenkounippon21/en/eiyouchousa/kekka_shintai_chousa_nendo.html. Accessed 14 Aug 2020.

  9. Tsujimoto T, Kajio H. Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF. J Am Coll Cardiol. 2017;70:2739–49.

    Article  Google Scholar 

  10. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29:1147–59.

    Article  Google Scholar 

  11. Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging. 2008;35:535–46.

    Article  Google Scholar 

  12. Alvarez GE, Ballard TP, Beske SD, Davy KP. Subcutaneous obesity is not associated with sympathetic neural activation. Am J Physiol Heart Circ Physiol. 2004;287:H414–8.

    Article  CAS  Google Scholar 

  13. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55:2212–21.

    Article  Google Scholar 

  14. Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, et al. A pooled analysis of multicenter cohort studies of (123)I-MIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging. 2013;6:772–84.

    Article  Google Scholar 

  15. Parker MW, Sood N, Ahlberg AW, Jacobson AF, Heller GV, Lundbye JB. Relationship between quantitative cardiac neuronal imaging with 123I-meta-iodobenzylguanidine and hospitalization in patients with heart failure. Eur J Nucl Med Mol Imaging. 2014;41:1666–72.

    Article  CAS  Google Scholar 

  16. Seo M, Yamada T, Tamaki S, Watanabe T, Morita T, Furukawa Y, et al. Prognostic significance of cardiac I-123-metaiodobenzylguanidine imaging in patients with reduced, mid-range, and preserved left ventricular ejection fraction admitted for acute decompensated heart failure: a prospective study in Osaka Prefectural Acute Heart Failure Registry (OPAR). Eur Heart J Cardiovasc Imaging. 2020:jeaa025.

  17. Komici K, Bencivenga L, Paolillo S, Gargiulo P, Formisano R, Assante R, et al. Impact of body mass index on cardiac adrenergic derangement in heart failure patients: a 123 I-MIBG imaging study. Eur J Nucl Med Mol Imaging. 2020;47:1713–21.

    Article  CAS  Google Scholar 

  18. Suna S, Hikoso S, Yamada T, Uematsu M, Yasumura Y, Nakagawa A, et al. Study protocol for the PURSUIT-HFpEF study: a prospective, multicenter, observational study of patients with heart failure with preserved ejection fraction. BMJ Open. 2020;10:e038294.

    Article  Google Scholar 

  19. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366:1059–62.

    Article  Google Scholar 

  20. Tamaki S, Yamada T, Okuyama Y, Morita T, Sanada S, Tsukamoto Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol. 2009;53:426–35.

    Article  CAS  Google Scholar 

  21. Masuda M, Yamada T, Mizuno H, Minamiguchi H, Konishi S, Ohtani T, et al. Impact of atrial fibrillation ablation on cardiac sympathetic nervous system in patients with and without heart failure. Int J Cardiol. 2015;199:65–70.

    Article  Google Scholar 

  22. Okuda K, Nakajima K, Hosoya T, Ishikawa T, Konishi T, Matsubara K, et al. Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac Iodine-123 MIBG imaging. J Nucl Cardiol. 2011;18:82–9.

    Article  Google Scholar 

  23. Nakajima K, Okuda K, Yoshimura M, Matsuo S, Wakabayashi H, Imanishi Y, et al. Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol. 2014;21:970–8.

    Article  Google Scholar 

  24. Bemelmans RH, van der Graaf Y, Nathoe HM, Wassink AM, Vernooij JW, Spiering W, et al. Increased visceral adipose tissue is associated with increased resting heart rate in patients with manifest vascular disease. Obesity. 2012;20:834–41.

    Article  Google Scholar 

  25. Nakajima K, Matsumoto N, Kasai T, Matsuo S, Kiso K, Okuda K. Normal values and standardization of parameters in nuclear cardiology: Japanese Society of Nuclear Medicine working group database. Ann Nucl Med. 2016;30:188–99.

    Article  Google Scholar 

  26. Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981;22:129–32.

    CAS  PubMed  Google Scholar 

  27. Marzullo P, Mariani G. From basic cardiac imaging to image fusion. Milano: Springer-Verlag Italia; 2013. p. 51–70.

    Book  Google Scholar 

  28. Roberts G, Lloyd JJ, Kane JPM, Durcan R, Lawley S, Howe K, et al. Cardiac (123)I-MIBG normal uptake values are population-specific: results from a cohort of controls over 60 years of age. J Nucl Cardiol. 2019. https://doi.org/10.1007/s12350-019-01887-6.

  29. Pellegrino T, Piscopo V, Boemio A, Russo B, De Matteis G, Pellegrino S, et al. Impact of obesity and acquisition protocol on (123)I-metaiodobenzylguanidine indexes of cardiac sympathetic innervation. Quant Imaging Med Surg. 2015;5:822–8.

    PubMed  PubMed Central  Google Scholar 

  30. Examination Committee of Criteria for “Obesity Disease” in Japan; Japan Society for the Study of Obesity. New criteria for “obesity disease” in Japan. Circ J. 2002;66:987–92.

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank Nagisa Yoshioka, Kyoko Tatsumi, Satomi Kishimoto, Noriko Murakami, and Sugako Mitsuoka for their excellent assistance with data collection. We thank Libby Cone, MD, MA, from DMC Corp. (www.dmed.co.jp <http://www.dmed.co.jp/>) for editing a draft of this manuscript.

The OCVC-Heart Failure Investigators: Shunsuke Tamaki, Tetsuya Watanabe, and Takahisa Yamada, Osaka General Medical Center, Osaka, Japan; Takaharu Hayashi and Yoshiharu Higuchi, Osaka Police Hospital, Osaka, Japan; Masaharu Masuda, Mitsutoshi Asai, and Toshiaki Mano, Kansai Rosai Hospital, Amagasaki, Japan; Hisakazu Fuji, Kobe Ekisaikai Hospital, Kobe, Japan; Daisaku Masuda, Yoshihiro Takeda, Yoshiyuki Nagai, and Shizuya Yamashita, Rinku General Medical Center, Izumisano, Japan; Masami Sairyo, Yusuke Nakagawa and Shuichi Nozaki, Kawanishi City Hospital, Kawanishi, Japan; Haruhiko Abe, Yasunori Ueda, Masaaki Uematsu, and Yukihiro Koretsune, National Hospital Organization Osaka National Hospital, Osaka, Japan; Kunihiko Nagai, Ikeda Municipal Hospital, Ikeda, Japan; Masamichi Yano, Masami Nishino, and Jun Tanouchi, Osaka Rosai Hospital, Sakai, Japan; Yoh Arita and Shinji Hasegawa, Japan Community Health Care Organization Osaka Hospital, Osaka, Japan; Takamaru Ishizu, Minoru Ichikawa and Yuzuru Takano, Higashiosaka City Medical Center, Higashiosaka, Japan; Eisai Rin, Kawachi General Hospital, Higashiosaka, Japan; Yukinori Shinoda and Shiro Hoshida, Yao Municipal Hospital, Yao, Japan; Masahiro Izumi, Kinki Central Hospital, Itami, Japan; Hiroyoshi Yamamoto and Hiroyasu Kato, Japan Community Health Care Organization, Osaka Minato Central Hospital, Osaka, Japan; Kazuhiro Nakatani and Yuji Yasuga, Sumitomo Hospital, Osaka, Japan; Mayu Nishio and Keiji Hirooka, Saiseikai Senri Hospital, Suita, Japan; Takahiro Yoshimura and Yoshinori Yasuoka, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan; Akihiro Tani, Kano General Hospital, Osaka, Japan; Yasushi Okumoto and Hideharu Akagi, Kinan Hospital, Tanabe, Japan; Yasunaka Makino, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan; Toshinari Onishi and Katsuomi Iwakura, Sakurabashi Watanabe Hospital, Osaka, Japan; Nagahiro Nishikawa and Yoshiyuki Kijima, Japan Community Health Care Organization, Hoshigaoka Medical Center, Hirakata, Japan; Takashi Kitao and Hideyuki Kanai, Minoh City Hospital, Minoh, Japan; Wataru Shioyama and Masashi Fujita, Osaka International Cancer Institute, Osaka, Japan; Koichiro Harada, Suita Municipal Hospital, Suita, Japan; Masahiro Kumada and Osamu Nakagawa, Toyonaka Municipal Hospital, Toyonaka, Japan; Ryo Araki and Takayuki Yamada, Otemae Hospital, Osaka, Japan; Akito Nakagawa and Yoshio Yasumura, Amagasaki Chuo Hospital, Amagasaki, Japan; and Taiki Sato, Akihiro Sunaga, Bolrathanak Oeun, Hirota Kida, Takayuki Kojima, Yohei Sotomi, Tomoharu Dohi, Kei Nakamoto, Katsuki Okada, Fusako Sera, Shinichiro Suna, Hidetaka Kioka, Tomohito Ohtani, Toshihiro Takeda, Daisaku Nakatani, Hiroya Mizuno, Shungo Hikoso, Yasushi Matsumura and Yasushi Sakata, Osaka University Graduate School of Medicine, Suita, Japan.

Code availability

Not applicable.

Funding

This study was funded by Roche diagnostic and FUJIFILM Toyama Chemical.

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan

    Akihiro Sunaga, Shungo Hikoso, Taiki Sato, Bolrathanak Oeun, Hirota Kida, Takayuki Kojima, Yohei Sotomi, Tomoharu Dohi, Katsuki Okada, Shinichiro Suna, Hiroya Mizuno, Daisaku Nakatani & Yasushi Sakata

  2. Division of Cardiology, Osaka General Medical Center, 3-1-56 Mandaihigashi, Sumiyoshi-ku, Osaka, 558-8558, Japan

    Takahisa Yamada

  3. Division of Cardiology, Amagasaki Chuo Hospital, 1-12-1 Sioe, Amagasaki, Hyogo, 660-0892, Japan

    Yoshio Yasumura

  4. Division of Cardiology, National Hospital Organization Osaka National Hospital, 2-1-14 Hoenzaka, Chuo-ku, Osaka, 540-0006, Japan

    Masaaki Uematsu & Haruhiko Abe

  5. Division of Cardiology, Kawanishi City Hospital, 5-21-1, Kawanishi, Hyogo, 666-0195, Japan

    Yusuke Nakagawa

  6. Cardiovascular Division, Osaka Police Hospital, 10-31 Kitayamacho, Tennojiku, Osaka, 543-0035, Japan

    Yoshiharu Higuchi

  7. Division of Cardiology, Kobe Ekisaikai Hospital, 1-21-1 Manabigaoka, Tarumi-ku, Kobe, 655-0004, Japan

    Hisakazu Fuji

  8. Kansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso, Amagasaki, 660-8511, Japan

    Toshiaki Mano

  9. Department of Medical Innovation, Osaka University Hospital, Suita, 2-15 Yamadaoka, Suita, 565-0871, Japan

    Hiroyuki Kurakami & Tomomi Yamada

  10. Department of Social and Environmental Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan

    Tetsuhisa Kitamura

Authors
  1. Akihiro Sunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shungo Hikoso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takahisa Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshio Yasumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masaaki Uematsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Haruhiko Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yusuke Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yoshiharu Higuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hisakazu Fuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Toshiaki Mano
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hiroyuki Kurakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tomomi Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Tetsuhisa Kitamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Taiki Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Bolrathanak Oeun
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Hirota Kida
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Takayuki Kojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Yohei Sotomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Tomoharu Dohi
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Katsuki Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Shinichiro Suna
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Hiroya Mizuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Daisaku Nakatani
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Yasushi Sakata
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the OCVC-Heart Failure Investigators

  • Shunsuke Tamaki
  • , Tetsuya Watanabe
  • , Takaharu Hayashi
  • , Masaharu Masuda
  • , Mitsutoshi Asai
  • , Daisaku Masuda
  • , Yoshihiro Takeda
  • , Yoshiyuki Nagai
  • , Shizuya Yamashita
  • , Masami Sairyo
  • , Shuichi Nozaki
  • , Yasunori Ueda
  • , Yukihiro Koretsune
  • , Kunihiko Nagai
  • , Masamichi Yano
  • , Masami Nishino
  • , Jun Tanouchi
  • , Yoh Arita
  • , Shinji Hasegawa
  • , Takamaru Ishizu
  • , Minoru Ichikawa
  • , Yuzuru Takano
  • , Eisai Rin
  • , Yukinori Shinoda
  • , Shiro Hoshida
  • , Masahiro Izumi
  • , Hiroyoshi Yamamoto
  • , Hiroyasu Kato
  • , Kazuhiro Nakatani
  • , Yuji Yasuga
  • , Mayu Nishio
  • , Keiji Hirooka
  • , Takahiro Yoshimura
  • , Yoshinori Yasuoka
  • , Akihiro Tani
  • , Yasushi Okumoto
  • , Hideharu Akagi
  • , Yasunaka Makino
  • , Toshinari Onishi
  • , Katsuomi Iwakura
  • , Nagahiro Nishikawa
  • , Yoshiyuki Kijima
  • , Takashi Kitao
  • , Hideyuki Kanai
  • , Wataru Shioyama
  • , Masashi Fujita
  • , Koichiro Harada
  • , Masahiro Kumada
  • , Osamu Nakagawa
  • , Ryo Araki
  • , Takayuki Yamada
  • , Akito Nakagawa
  • , Kei Nakamoto
  • , Fusako Sera
  • , Hidetaka Kioka
  • , Tomohito Ohtani
  • , Toshihiro Takeda
  •  & Yasushi Matsumura

Contributions

Akihiro Sunaga: conceptualization, formal analysis, investigation, methodology, project administration, visualization, writing—original draft. Shungo Hikoso: project administration, supervision, writing—review & editing. Takahisa Yamada: resources, supervision, writing—review & editing. Yoshio Yasumura, resources, writing—review & editing. Masaaki Uematsu; Resources, writing—review & editing. Haruhiko Abe; Resources, writing—review & editing. Yusuke Nakagawa, Resources, writing—review & editing. Yoshiharu Higuchi: resources, writing—review & editing. Hisakazu Fuji; Resources, writing—review & editing. Toshiaki Mano; Resources, writing—review & editing. Hiroyuki Kurakami: data curation, formal analysis. Tomomi Yamada: data curation, formal analysis. Tetsuhisa Kitamura: writing—review & editing. Taiki Sato: writing—review & editing. Bolrathanak Oeun: writing—review & editing. Hirota Kida: writing—review & editing. Takayuki Kojima; writing—review & editing. Yohei Sotomi: data curation, writing—review & editing. Tomoharu Dohi: writing—review & editing. Katsuki Okada: writing—review & editing. Shinichiro Suna: writing—review & editing. Hiroya Mizuno: writing—review & editing. Daisaku Nakatani: writing—review & editing. Yasushi Sakata: funding acquisition, project administration, supervision, writing—review & editing.

Corresponding author

Correspondence to Shungo Hikoso.

Ethics declarations

Ethics approval

The protocol was approved by the Institutional Review Board (IRB) of Osaka University Hospital on 24 February 2016 (ID: 15471), and by the IRBs of the all participating facilities.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent for publication

Consent for publication was obtained from all individual participants included in the study.

Conflict of interest

Shungo Hikoso has received remuneration from Daiichi Sankyo Company, and received research funding from Roche Diagnostics, FUJIFILM Toyama Chemical, and Actelion Pharmaceuticals. Yoshiharu Higuchi has received remuneration from Daiichi Sankyo Company. Hiroya Mizuno has received endowed department from Terumo. Yohei Sotomi has received remuneration from Abbott Vascular Japan, Boston Scientific Japan, and received research funding from Abbott Vascular Japan, and endowed department form Terumo. Yasushi Sakata received remuneration from Otsuka Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo Company and AstraZeneca K.K., and received research funding form Otsuka Pharmaceutical, Daiichi Sankyo Company, Mitsubishi Tanabe Pharma Corporation, Astellas Pharma, Kowa Company, Boehringer Ingelheim Japan, and Biotronik. The other authors have nothing to declare.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Cardiology

Supplementary information

ESM 1

(XLSX 49.9 kb)

ESM 2

(XLSX 20.5kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sunaga, A., Hikoso, S., Yamada, T. et al. Abdominal obesity, and not general obesity, is associated with a lower 123I MIBG heart-to-mediastinum ratio in heart failure patients with preserved ejection fraction. Eur J Nucl Med Mol Imaging 49, 609–618 (2022). https://doi.org/10.1007/s00259-021-05280-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-021-05280-9

Keywords

Search

Navigation